Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets.

We studied the attenuation, immunogenicity and efficacy of the cold-adapted A/Ann Arbor/6/60 (AA ca) (H2N2) virus in mice and ferrets to evaluate its use in the event of an H2 influenza pandemic. The AA ca virus was restricted in replication in the respiratory tract of mice and ferrets. In mice, 2 doses of vaccine elicited a >4-fold rise in hemagglutination-inhibition (HAI) titer and resulted in complete inhibition of viral replication following lethal homologous wild-type virus challenge. In ferrets, a single dose of the vaccine elicited a >4-fold rise in HAI titer and conferred complete protection against homologous wild-type virus challenge in the upper respiratory tract. In both mice and ferrets, the AA ca virus provided significant protection from challenge with heterologous H2 virus challenge in the respiratory tract. The AA ca vaccine is safe, immunogenic, and efficacious against homologous and heterologous challenge in mice and ferrets, supporting the evaluation of this vaccine in clinical trials.

[1]  W. Dowdle.  Influenza A virus recycling revisited. , 1999, Bulletin of the World Health Organization.

[2]  K G Nicholson,et al.  Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin , 2003, Journal of medical virology.

[3]  C. Scholtissek,et al.  On the origin of the human influenza virus subtypes H2N2 and H3N2. , 1978, Virology.

[4]  Lihan K. Yan,et al.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. , 2000, The Journal of infectious diseases.

[5]  Ron A M Fouchier,et al.  Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans , 2009, Science.

[6]  A. Takada,et al.  H2N5 influenza virus isolates from terns in Australia: genetic reassortants between those of the Eurasian and American lineages , 2008, Virus Genes.

[7]  Gabriele Neumann,et al.  Emergence and pandemic potential of swine-origin H1N1 influenza virus , 2009, Nature.

[8]  R. Webster,et al.  Influenza virus subtypes in aquatic birds of eastern Germany , 2005, Archives of Virology.

[9]  M. Eichelberger,et al.  FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. , 2008, Vaccine.

[10]  H. Maassab,et al.  Biologic and immunologic characteristics of cold-adapted influenza virus. , 1969, Journal of immunology.

[11]  H. Maassab,et al.  Infant rat model of attenuation for recombinant influenza viruses prepared from cold-adapted attenuated A/Ann Arbor/6/60 , 1982, Infection and immunity.

[12]  B. Murphy,et al.  Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. , 2002, Viral immunology.

[13]  R. Webster,et al.  Predictions for future human influenza pandemics. , 1997, The Journal of infectious diseases.

[14]  H. Maassab,et al.  Adaptation and Growth Characteristics of Influenza Virus at 25° C , 1967, Nature.

[15]  K. Subbarao,et al.  A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. , 2008, Virology.

[16]  J. Stoddard,et al.  Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine , 2004, Expert review of vaccines.

[17]  H. Maassab,et al.  The development of live attenuated cold‐adapted influenza virus vaccine for humans , 1999, Reviews in medical virology.

[18]  R. Webster,et al.  Transmission of Eurasian avian H2 influenza virus to shorebirds in North America. , 1999, The Journal of general virology.

[19]  Clayton W Naeve,et al.  Influenza in Migratory Birds and Evidence of Limited Intercontinental Virus Exchange , 2007, PLoS pathogens.

[20]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[21]  R. Webster,et al.  Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics , 1989, Journal of virology.

[22]  W. J. Bean,et al.  Origin of the pandemic 1957 H2 influenza A virus and the persistence of its possible progenitors in the avian reservoir. , 1993, Virology.

[23]  A. Monto,et al.  Evaluation of a cold-recombinant influenza virus vaccine in ferrets. , 1982, The Journal of infectious diseases.

[24]  R. Hornick,et al.  Low-Temperature-Adapted Influenza A2/AA/6/60 Virus Vaccine in Man , 1973, Infection and immunity.

[25]  B. Murphy,et al.  Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets , 2006, PLoS medicine.

[26]  W. J. Bean,et al.  Evolutionary processes in influenza viruses: divergence, rapid evolution, and stasis. , 1992, Current topics in microbiology and immunology.

[27]  Gendon IuZ.  [Live cold-adapted reassortant influenza vaccines]. , 2001 .

[28]  N. Cox,et al.  Global epidemiology of influenza: past and present. , 2000, Annual review of medicine.

[29]  Chin-fen Yang,et al.  Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. , 2003, Virology.

[30]  H. Maassab,et al.  Adaptation and growth characteristics of influenza virus at 25 degrees c. , 1967, Nature.

[31]  Y. H. Zhang,et al.  Humoral and cellular responses of mice to infection with a cold-adapted influenza A virus variant , 1982, Infection and immunity.